尼拉帕利一线维持治疗铂敏感广泛期小细胞肺癌的随机双盲III期研究
ZL-2306-005 是评估尼拉帕利对比安慰剂用于中国铂敏感广泛期小细胞肺癌(ES-SCLC)一线维持治疗的随机双盲多中心III期研究。因治疗格局变化提前终止,共随机185例(尼拉帕利125例、安慰剂60例)。盲态独立中心评估中位无进展生存期(PFS)尼拉帕利1.54个月 vs 安慰剂1.36个月(HR=0.66,95%CI 0.46-0.95,p=0.0242),总生存期(OS)无获益(HR=1.03,95%CI 0.62-1.73,p=0.9052),≥3级不良事件发生率34.4% vs 25.0%。
要点
- 尼拉帕利维持治疗仅轻度改善铂敏感ES-SCLC的PFS,HR=0.66
- 总生存期无获益,HR=1.03(95%CI 0.62-1.73,p=0.9052)
- ≥3级不良事件发生率尼拉帕利34.4%、安慰剂25.0%
核心结论
- ZL-2306-005未达到主要终点,尼拉帕利维持治疗在铂敏感ES-SCLC中仅轻度改善PFS,OS无获益,耐受性可接受且无新安全信号。
研究设计与样本
- 随机、双盲、多中心III期研究,计划样本量591例,实际随机185例(尼拉帕利125例、安慰剂60例),按2:1分配。
- 入组为一线铂类标准化疗后达完全缓解(CR)或部分缓解(PR)的中国ES-SCLC患者,随机接受尼拉帕利或安慰剂每日一次直至进展或不可耐受毒性。
- 主要终点为盲态独立中心评估的PFS和OS,次要终点包括研究者评估的PFS和安全性;研究因ES-SCLC治疗格局变化提前终止(数据截止2020年3月20日)。
主要发现
- 盲态独立中心评估中位PFS:尼拉帕利1.54个月(95%CI 1.41-2.69)vs 安慰剂1.36个月(95%CI 1.31-1.48),HR=0.66(95%CI 0.46-0.95,p=0.0242)。
- 中位OS:尼拉帕利9.92个月(95%CI 9.33-13.54)vs 安慰剂11.43个月(95%CI 9.53-不可估计),HR=1.03(95%CI 0.62-1.73,p=0.9052)。
- 研究者评估中位PFS:尼拉帕利1.48个月(95%CI 1.41-2.56)vs 安慰剂1.41个月(95%CI 1.31-2.00),HR=0.88(95%CI 0.61-1.26,p=0.4653)。
- ≥3级不良事件发生率:尼拉帕利34.4%,安慰剂25.0%。
临床怎么用
- 该研究未达到主要终点且提前终止,尼拉帕利维持治疗在铂敏感ES-SCLC中PFS改善幅度有限且OS无获益,不支持其作为该人群的常规维持治疗选择。
局限性
- 研究因ES-SCLC治疗格局变化提前终止,实际随机185例远低于计划样本量591例,统计效能受限。
- 研究仅纳入中国患者,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: ZL-2306-005 is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with platinum-responsive, extensive-stage SCLC (ES-SCLC). METHODS: Patients with complete response (CR) or partial response (PR) to standardized, platinum-based first-line chemotherapy were randomized 2:1 to receive niraparib or placebo (300 mg [baseline body weight ≥ 77 kg, platelet count ≥ 150,000/μL] or 200 mg) once daily until progression or unacceptable toxicity. Primary end points were progression-free survival (PFS) (blinded independent central review) and overall survival (sample size planned: 591 patients). Secondary end points included investigator-evaluated PFS and safety. RESULTS: ZL-2306-005 was terminated early owing to ES-SCLC treatment landscape changes (data cutoff: March 20, 2020). During July 2018-February 2020, a total of 185 of 272 patients screened were randomized (niraparib: n = 125 [CR = 1, PR = 124]; placebo: n = 60 [CR = 1, PR = 59]). Median (95% confidence interval [CI]) PFS (blinded independent central review) was 1.54 months (1.41-2.69, niraparib) and 1.36 months (1.31-1.48, placebo); hazard ratio (HR) = 0.66 (95% CI: 0.46-0.95, p = 0.0242). Median overall survival was 9.92 months (9.33-13.54, niraparib) and 11.43 months (9.53-not estimable, placebo); HR = 1.03 (95% CI: 0.62-1.73, p = 0.9052). Median investigator-evaluated PFS was 1.48 months (1.41-2.56, niraparib) and 1.41 months (1.31-2.00, placebo); HR = 0.88 (95% CI: 0.61-1.26; p = 0.4653). Grade greater than or equal to 3 adverse events occurred in 34.4% (niraparib) and 25.0% (placebo) of patients. CONCLUSIONS: ZL-2306-005 did not reach primary end points. Nevertheless, niraparib as maintenance therapy modestly improved PFS in patients with platinum-responsive ES-SCLC, with acceptable tolerability profile and no new safety signal.
引用
- Ai X, Pan Y, Shi J, et al. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. J Thorac Oncol. 2021. PMID: 33915252. doi:10.1016/j.jtho.2021.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。